Medici Therapeutics, Inc. is a biotechnology company focused on developing advanced cancer treatments within the immunotherapy sector. The company's primary focus is on advancing tumor-infiltrating lymphocyte (TIL) therapies by leveraging novel insights into cancer immunology, particularly how cancer cells evade immune responses.
The company is developing an adoptive cell therapy where a patient's own immune cells (lymphocytes) are extracted from their tumor, expanded in a laboratory setting, and then re-infused to attack the cancer. A key aspect of their development process is a novel enhancement technique that infuses the TILs with healthy mitochondria to counteract a mechanism cancer cells use to disable T cells, thereby improving therapeutic potency.
This therapy addresses the problem of T cell exhaustion and immune evasion in cancer patients, particularly a mechanism where cancer cells transfer dysfunctional mitochondria to T cells. By reversing this sabotage, the therapy aims to create a more effective and lasting anti-tumor response for patients with limited treatment options.
The addressed pain points include the limited efficacy of conventional cancer therapies and the ability of tumors to develop resistance by evading the body's natural immune system. The company's approach specifically tackles the issue of T cell dysfunction caused by interactions with cancer cells.